NEW HAVEN, Conn.--(BUSINESS WIRE)--Rib-X Pharmaceuticals, Inc. announced that results from the Company’s RX-04 development program will be featured today in the Novel Antimicrobial Agents poster session at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA) being held in Boston, Mass. on October 20-23, 2011. The study, conducted by researchers at Hartford Hospital, demonstrated that three representative RX-04 compounds possessed greater in vitro potency (MIC distributions ranged from 2-8 µg/mL) than currently utilized antimicrobials for Pseudomonas aeruginosa respiratory infections. The compounds were tested against hospital-derived respiratory isolates, including multi-drug resistant (MDR) strains. P. aeruginosa is a common cause of pneumonia in the hospital setting and is associated with high rates of morbidity and mortality.
